Pre-Conference Seminar Day

Monday, August 29, 2022

Seminar Day

Repairing & Regenerating Lung Tissue – The Future of IPF Therapeutics

8:25 am Chair’s Opening Remarks

Halting & Reversing Disease Progression to Achieve Lung Regeneration

8:30 am Advancing the Understanding of the Pathology & Molecular Mechanisms of IPF to Identify Potential Targets

  • Matthew Thomas Head of Immunology & Respiratory Diseases Research for Germany, Boehringer Ingelheim

Synopsis

  • Promoting tissue repair and lung regeneration through pathological and molecular mechanisms unique to IPF
  • Understanding the fundamental mechanistic differences between healthy and diseased cells to encourage repair
  • Divulging practical strategies to identify potential targets for reversing disease degeneration
  • Highlighting the necessity for precision medicine in an era of multiple therapeutics on the market

9:00 am Modeling Approaches in Repair & Regeneration

  • Oliver Eickelberg Professor of Medicine & Vice Chair of Basic & Translational Sciences, University of Pittsburgh

Synopsis

  • Reviewing studies involving complex phenotypic models simulating aspects of IPF, such as human lung organoids, human lung tissue ex vivo cultures and co-culture systems to inform why the lung environment is hostile to normal repair
  • Using animal models to recapitulate drivers of lung fibrosis within the lung environment
  • Reflecting on the use of human samples vs. rodent samples; and the repercussions for translatability
  • Comparing the bleomycin model to other emerging animals models of lung fibrosis

9:30 am Stromal-Epithelial Interactions & Cellular Bioenergetics in Lung Regeneration

Synopsis

  • Understanding the crosstalk between the epithelium and mesenchyme to inform lung regeneration
  • Highlighting the fates of reparative cells determine the outcome of the repair process

10:00 am
Morning Break & Structured Networking

10:50 am Optimized Synthetic Flavanols Support Senolytic Clearance & Lung Fibrosis Resolution

Synopsis

  • Exploring the limitations of naturally derived flavanols as senolytic and antifibrotic therapies
  • Discussing hit-to-lead and medicinal chemistry approaches toward developing a potent and metabolically stable senolytic flavonol
  • Divulging in vivo efficacy and hints at understanding the cellular and molecular mechanism of senolytic flavanols

11:00 am Discussion Panel:What Next Steps do we Need to Take to Navigate Lung Repair & Regeneration?

  • Matthew Thomas Head of Immunology & Respiratory Diseases Research for Germany, Boehringer Ingelheim
  • Oliver Eickelberg Professor of Medicine & Vice Chair of Basic & Translational Sciences, University of Pittsburgh
  • Viktor Thannickal Professor, Tulane University School of Medicine

Rethinking Senescence to Effectively Repair & Regenerate Lung Tissue in IPF

11:50 am New Drugs for Old Cells – Oligonucleotide Senotherapeutics for Fibrotic Lung Diseases

Synopsis

  • Highlighting how cellular senescence is a major contributor to ECM dysfunction, inflammation, and lung fibrosis
  • Exploring how Dysregulated RNA processing is a new hallmark of ageing which drives senescence and can be drugged for rejuvenation of senescent cells
  • Harnessing the power of oligonucleotide therapeutics to reprogram splicing regulation and restore function to aged primary human lung cells

12:20 pm
Lunch & Networking

1:20 pm Enlightening the Pharmacotherapies Targeting Senescence Cells

Synopsis

  • Reimagining what strategies should be used to either target the destruction of the senescence cell or mitigate the products that senescence makes
  • Understanding the biology of the pharmacotherapies and mechanisms of action
  • Discovering what these therapies could mean for IPF drug development

1:50 pm Discussion Panel:Giving Aging Cells a New Sense of Life – The Importance of Senescence for Lung Repair & Regeneration

Unlocking Cell Therapies & Considering Disease Translatability for Repair & Regeneration

2:20 pm Targeting Epithelial Repair & Regeneration

  • Glenn Rosen Chief Scientific Officer, Optikira LLC and Anteros Therapeutics

Synopsis

  • Describing the translational relevance of new research into lung stem cells to promote epithelial repair and regeneration
  • Discussing the development of novel therapeutics to promote epithelial repair and regeneration in ILD
  • Exploring translational biomarkers associated with epithelial repair and regeneration

2:50 pm
Afternoon Break

3:20 pm Long-Term Partial Reprogramming Leads to Rejuvenating Effects: Determining the Translatability to Future IPF Research

Synopsis

  • Session details to be confirmed

3:50 pm Cutting-Edge Cell Based Therapies for IPF

  • Marilyn K. Glassberg The John W. Clarke Professor of Medicine, Chair, Department of Medicine, Loyola University

Synopsis

  • Discovering mesenchymal stromal cell (MSC) therapies for the tissue repair and regeneration of IPF
  • Reviewing the safety and early efficacy results of pulmonary diseases
  • Highlighting the promise of MSCs as a therapeutic approach for IPF

4:20 pm Panel Discussion:Supercharging Repair & Regeneration Therapies to IPF Patients

  • Glenn Rosen Chief Scientific Officer, Optikira LLC and Anteros Therapeutics
  • Kristen Browder Principal Scientific Researcher, Genentech
  • Marilyn K. Glassberg The John W. Clarke Professor of Medicine, Chair, Department of Medicine, Loyola University

4:45 pm Chair’s Closing Remarks

Pre-Conference Workshop Day

Monday, August 29, 2022

Workshop Day

9.00 – 12.00 Workshop A: Broadening the IPF Therapeutic Horizon: Is there Translatability to COPD, Asthma & Cough?

Expand the horizons of your drug development pipeline by investigating growing drug development opportunity in COPD, Asthma and cough. Leave this session with the knowledge, hypotheses, and detail you need to create an undisputed respiratory pipeline and supercharge therapeutics to patients in need.

Exploring the Opportunity & Discussing the Translatability of IPF Therapeutic Approaches to Treating Patients with COPD

Synopsis

  • Exploring the effects of Small Mobile Stem (SMS) cells on alveoli cells that could translate into lung fibrosis treatment
  • Uncovering the translatability of SMS cell therapeutic approach for COPD
  • Considering the molecular mechanism of action of SMS cells at gene expression level, what are the prospects for an IPF cell therapy

Navigating the Pre-Clinical Challenges of Transferring IPF Research & Development to Asthma Indications

Synopsis

  • Leveraging IPF therapeutic approaches in Asthma
  • Discussing the potential of the approaches

Approaching Chronic Cough with a Fresh Mindset to Bring New Therapeutics to Light

Synopsis

  • Discussing the pathophysiology of cough and potential mechanisms
  • Review the importance of objective measurements of cough frequency and patient reported outcomes
  • Assess the need for therapies to improve quality of life in IPF patients

Lunch & Networking

13.00 – 16.00 Workshop B: IPF the Archetypal Fibrotic Disease: Reconsidering IPF Research for Other Types of ILD

Calling all ILD enthusiasts. As IPF is hailed the archetypal fibrotic disease, why not add other ILD therapeutics to the pipeline? Join this workshop to harness the relevant knowledge needed to understand the challenges currently facing the ILD field as a whole and how this is separate to the challenges often faced in IPF

Highlights Include:

Synopsis

  • Exploring early detection and identification of pulmonary fibrosis
  • Comparing inflammatory and fibrotic ILD data
  • Highlighting the role of immune cells in ILD and fibrosis
  • Unlocking IPF as the key to succeed in other types of ILD by capturing the translatability of therapeutics
  • Investigating ILD biomarkers to understand trial populations
  • Identifying endpoints which are likely to predict clinical success
  • Considering when resolution of inflammation goes wrong
  • Understanding the RA-ILD biomarkers, genetics, proteomics, and therapeutics currently available
  • Cultivating effective therapeutics that reflect the unique patient populations of interstitial lung disease